产品说明书

OTX008

Print
Chemical Structure| 286936-40-1 同义名 : Calixarene 0118;PTX008;N(2dimethylamino)ethyl)acetamidyl calix4arene.
CAS号 : 286936-40-1
货号 : A1177354
分子式 : C52H72N8O8
纯度 : 99%+
分子量 : 937.177
MDL号 : MFCD28396412
存储条件:

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 4 mg/mL(4.27 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

无水乙醇: 30 mg/mL(32.01 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇

动物实验配方:
生物活性
描述 Galectin-1 is a member of a family of evolutionarily conserved glycan-binding proteins, displays broad anti-inflammatory and pro-resolving activities by targeting multiple immune cell types[1]. Galectin-1 is also a carbohydrate-binding protein is implicated in cancer cell proliferation, invasion and tumor angiogenesis. OTX008 is a calixarene-based compound and selective galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. OTX008 inhibited tumor cell proliferation, though inhibition was very variable, with IC50 ranging from 1.7 to 192.3 μM. In vivo, the human ovarian carcinoma A2780-1A9 and human glioblastoma U87MG showed a different degree of sensitivity to OTX008 (IC50 of 2.1 and 35.8 μM, respectively). OTX008 achieved a Cmax of 14.39 μg/mL (15.35 μM) and then the drug was rapidly distributed through the body with half-life (HL) of 20 min and cleared from plasma with a long elimination HL of 31.4 h. In vitro, OTX008 inhibited endothelial cell proliferation in a concentration-dependent manner with a mean IC50 values of 9.9 ± 4.2, 8.7 ± 1.7, and 12.9 ± 3.3 μM respectively[2].

实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.07mL

0.21mL

0.11mL

5.34mL

1.07mL

0.53mL

10.67mL

2.13mL

1.07mL

参考文献

[1]Sundblad, V., Morosi, L., Geffner, J., et al. Galectin-1: A Jack-of-All-Trades in the Resolution of Acute and Chronic Inflammation. J Immunol December 1, 2017, 199 (11) 3721-3730.

[2]Zucchetti M, Bonezzi K, Frapolli R, et al. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 2013;72(4):879-887.